Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.2.1.36 (hyaluronidase)
4,606 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of 2 different levels of serum hyaluronidase on tumor development was studied by comparing the development of 2 transplantable tumors, the 3LL lung carcinoma and the B16F10 melanoma, in mice of the C57BL/6 and the congenic HW23 strains. The reasoning behind the study was that, in vitro, removal by hyaluronidase of the hyaluronan present in the extracellular matrix of tumor cells renders the latter more accessible to effector T cells. In the mouse, the levels and molecular forms of circulating hyaluronidase are under the influence of different alleles at the Hyal-1 locus on chromosome 9. C57BL/6 mice which have the Hyal-1b allele have only a 60,000-kDa form of hyaluronidase in the circulation, whereas the congenic HW23 strain has, on a C57BL/6 background, the BALB/c-derived Hyal-1a allele, characterized by the presence of the 60-, 120- and 140-kDa forms and of 3 times as much enzyme activity as the C57BL/6 strain. These 2 mouse strains that are genetically almost identical can therefore be used to compare the effect of different levels of circulating hyaluronidase on tumor development. Two different tumors were studied: the 3LL lung carcinoma and the B16F10 melanoma. After intrafootpad inoculation, both tumors developed more slowly in the congenic Hyal-1a HW23 strain, as measured by a slower rate of increase in local tumor size and by a prolonged survival time. These results are in favor of the hypothesis that the Hyal-1a allele, determining higher hyaluronidase levels, enhances resistance to tumor development.
...
PMID:The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and polymorphism. 160 26

We have recently described a new locus, Hyal-1, which determines hyaluronidase variants in mouse serum. On the basis of segregation in recombinant inbred and congenic strains, Hyal-1 was tentatively assigned to chromosome 9 (Fiszer-Szafarz and De Maeyer, '89). In the present study we have performed a linkage analysis of Hyal-1 using 156 backcross progeny of an interspecies cross of laboratory mice and Mus Spretus. Linkage was tested to two anchor loci on chromosome 9: d (dilute, a coat color locus) and Bgl-s (a locus controlling beta-galactosidase activity). The gene order (from centromere) with intervening percentage recombination is d-16.6 (+/- 2.9)-Hyal-1-10.9 (+/- 2.4)-Bgl-s, indicating close linkage to H-7 and Fv-2.
...
PMID:Linkage analysis of the murine Hyal-1 locus on chromosome 9. 202 49

Analysis of mouse serum hyaluronidase by polyacrylamide gel electrophoresis, with the substrate high-molecular-weight hyaluronan (hyaluronic acid) included in the gel performed in mice of two different strains, BALB/cBy and C57BL/6By, reveals a pattern of multiple enzyme forms specific for each genotype. In BALB/c serum, seven different forms are present, only one of which is found in C57BL/6 serum. Segregation analysis of the enzyme polymorphism in backcross progeny and in recombinant inbred and bilineal congenic lines shows that the difference is due to a single locus, which we have designated as Hyal-1. Hyal-1 is linked to the histocompatibility locus H-7, on chromosome 9.
...
PMID:Hyal-1, a locus determining serum hyaluronidase polymorphism, on chromosome 9 in mice. 291 64

The Hyal-1 locus, which we have previously described and mapped to mouse chromosome 9, influences the serum levels and molecular weight forms of hyaluronidase. We have also shown that the growth of two transplantable tumors, the 3LL carcinoma and the B16F10 melanoma, is influenced by the alleles at Hyal-1, in that the tumors develop more slowly in congenic B6.C-Hyal-1a (also called HW23) mice than in the parental Hyal-1b C57BL/6 mice. Here we present evidence that tumor development is stimulated and mortality is accelerated in B6.C-Hyal-1a mice grafted with 3LL carcinoma cells when treated with alpha/beta interferon (IFN-alpha/beta) or with IFN-beta, whereas in IFN-treated C57BL/6 mice 3LL tumor growth is inhibited. Likewise, in B6.C-Hyal-1a mice grafted with B16F10 melanoma cells, IFN-alpha/beta treatment results in stimulation of tumor growth, whereas in IFN-treated C57BL/6 mice tumor growth, whereas in IFN-treated C57BL/6 mice tumor growth is inhibited and mortality delayed. Thus, IFN-alpha/beta treatment of B6.C-Hyal-1a mice results in stimulation of tumor development and sometimes in accelerated mortality. This is the opposite of the usually described effect of IFN treatment in mice, which is inhibition of tumor development and delayed mortality, as was indeed observed in the C57BL/6 mice in the present experiments. These results provide the first indication that host genes can up- or down-regulate the antitumor activity of IFN and that, on some genetic backgrounds, IFN treatment enhances rather than inhibits tumor development. This may help to explain the apparent discordance between mouse model studies, which hitherto have consistently reported inhibition of tumor formation by IFN, and the clinical trials, in which only a limited percentage of individuals show tumor regression while others have no beneficial effect or even have progression of disease in spite of the IFN treatment.
...
PMID:Accelerated tumor development in interferon-treated B6.C-Hyal-1 a mice. 851 20

Hyaluronidase was purified from human plasma using Triton X-114 phase extractions and ion-exchange chromatography. Monoclonal antibodies generated against the purified protein by a novel screening assay were utilized to isolate homogeneous enzyme for microsequencing. The amino acid sequences obtained matched a cDNA in the Expressed Sequence Tag database which, with 5'-RACE-PCR, was used to clone the plasma hyaluronidase gene, termed Hyal-1. Hyal-1 codes for a protein of 435 amino acids that is over 40% identical to PH-20, a sperm-specific hyaluronidase. Unlike PH-20, which is only expressed in testis, transcripts of Hyal-1 were found in multiple tissues. Hyal-1 stably expressed in human embryonic kidney cells resulted in a 3,000 fold increase of secreted immunoreactive hyaluronidase activity that was biochemically indistinguishable from human plasma hyaluronidase. By immunological, molecular and biochemical criteria, we conclude that Hyal-1 is the predominant hyaluronidase found in human plasma.
...
PMID:Purification, cloning, and expression of human plasma hyaluronidase. 922 16

Hyaluronidase activity has been detected for the first time in normal human dermal fibroblasts (HS27), as well as in fetal fibroblasts (FF24) and fibrosarcoma cells (HT1080). Enzymatic activity was secreted predominantly into the culture media, with minor amounts of activity associated with the cell layer. In both classes of fibroblasts, hyaluronidase expression was confluence-dependent, with highest levels of activity occurring in quiescent, post-confluent cells. However, in the fibrosarcoma cell cultures, expression was independent of cell density. The enzyme had a pH optimum of 3.7 and on hyaluronan substrate gel zymography, activity occurred as a single band corresponding to an approximate molecular size of 57 kDa. The enzyme could be immunoprecipitated in its entirety using monoclonal antibodies raised against Hyal-1, human plasma hyaluronidase. PCR confirmed that fibroblast hyaluronidase was identical to Hyal-1. The conclusion by previous investigators using earlier technologies that fibroblasts do not contain hyaluronidase activity should be reevaluated.
...
PMID:Hyaluronidase expression in human skin fibroblasts. 1058 Dec 1

The hyaluronidase first isolated from human plasma, Hyal-1, is expressed in many somatic tissues. The Hyal-1 gene, HYAL1, also known as LUCA-1, maps to chromosome 3p21.3 within a candidate tumor suppressor gene locus defined by homozygous deletions and by functional tumor suppressor activity. Hemizygosity in this region occurs in many malignancies, including squamous cell carcinomas of the head and neck. We have investigated whether cell lines derived from such malignancies expressed Hyal-1 activity, using normal human keratinocytes as controls. Hyal-1 enzyme activity and protein were absent or markedly reduced in six of seven carcinoma cell lines examined. Comparative genomic and fluorescence in situ hybridization identified chromosomal deletions of one allele of HYAL1 in six of seven cell lines. Initial RT - PCR analyses demonstrated marked discrepancies between levels of HYAL1 mRNA and protein. Despite repeated sequence analyses, no mutations were found. However, two species of transcripts were identified when primers were used that included the 5' untranslated region. The predominant mRNA species did not correlate with protein translation and contained a retained intron. A second spliced form lacking this intron was found only in cell lines that produced Hyal-1 protein. Inactivation of HYAL1 in these tumor lines is a result of incomplete splicing of its pre-mRNA that appears to be epigenetic in nature. Oncogene (2000) 19, 870 - 877.
...
PMID:HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. 1070 95

Paradoxically, both hyaluronan (HA) and hyaluronidase are involved in malignant transformation and cancer progression. Their mechanisms of action, given the apparent disparities, are not understood. In many malignancies, levels of HA correlate with metastatic behavior while hyaluronidases suppress malignant progression. Hyal-1, product of one of six paralogous hyaluronidase-like sequences, is the predominant circulating hyaluronidase. HYAL1, the gene that codes for Hyal-1, is located on chromosome 3p21.3, a region containing a tumor suppressor gene. Loss of HYAL1 often correlates with tumor progression, particularly in tobacco-related cancers. In other malignancies, however, hyaluronidase functions as a tumor promoter. Testicular hyaluronidase (PH-20), used as an adjuvant in chemotherapy, is assumed to enhance drug permeability. By an unknown mechanism, hyaluronidases recruit tumor cells back into the cycling pool, making these malignancies more sensitive to chemotherapeutic drugs. Such contradictory observations might be resolved by assuming that HA and hyaluronidase are required at different times in the multiple steps that lead to malignant transformation. We have undertaken a systematic investigation of their roles in cancer progression. Here, we investigate the effect of Hyal-1 expression on cell cycle kinetics. A tumor cell line was constructed with an ecdysone-inducible promoter located upstream from the cDNA of HYAL1. Fluorescent-activated cell sorting was used to monitor cell cycle kinetics following Hyal-1 induction. Enhanced cell cycling was observed, with a 13.6% increase in S phase and 9.6% decrease in G(1)/G(0) phase cells.
...
PMID:Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. 1116 12

The human genome contains six hyaluronidase-like genes. Three genes (HYAL1, HYAL2 and HYAL3) are clustered on chromosome 3p21.3, and another two genes (HYAL4 and PH-20/SPAM1) and one expressed pseudogene (HYALP1) are similarly clustered on chromosome 7q31.3. The extensive homology between the different hyaluronidase genes suggests ancient gene duplication, followed by en masse block duplication, events that occurred before the emergence of modern mammals. Very recently we have found that the mouse genome also has six hyaluronidase-like genes that are also grouped into two clusters of three, in regions syntenic with the human genome. Surprisingly, the mouse ortholog of HYALP1 does not contain any mutations, and unlike its human counterpart may actually encode an active enzyme. Hyal-1 is the only hyaluronidase in mammalian plasma and urine, and is also found at high levels in major organs such as liver, kidney, spleen, and heart. A model is proposed suggesting that Hyal-2 and Hyal-1 are the major mammalian hyaluronidases in somatic tissues, and that they act in concert to degrade high molecular weight hyaluronan to the tetrasaccharide. Twenty-kDa hyaluronan fragments are generated at the cell surface in unique endocytic vesicles resulting from digestion by the glycosylphosphatidyl-inositol-anchored Hyal-2, transported intracellularly by an unknown process, and then further digested by Hyal-1. The two beta-exoglycosidases, beta-glucuronidase and beta-N-acetyl glucosaminidase, remove sugars from reducing termini of hyaluronan oligomers, and supplement the hyaluronidases in the catabolism of hyaluronan.
...
PMID:The six hyaluronidase-like genes in the human and mouse genomes. 1173 Dec 67

Hyaluronidase is a hyaluronic acid-degrading endoglycosidase that is present in many toxins and the levels of which are elevated in cancer. Increased concentration of HYAL1-type hyaluronidase correlates with tumor progression and is a marker for grade (G) 2 or 3 bladder cancer. Using bladder tissues and cells, prostate cancer cells, and kidney tissues and performing reverse transcription-PCR, cDNA cloning, DNA sequencing, and in vitro translation, we identified splice variants of HYAL1 and HYAL3. HYAL1v1 variant lacks a 30-amino acid (aa) sequence (301-330) present in HYAL1 protein. HYAL1v1, HYAL1v2 (aa 183-435 present in HYAL1 wild type), HYAL1v3 (aa 1-207), HYAL1v4 (aa 260-435), and HYAL1v5 (aa 340-435) are enzymatically inactive and are expressed in normal tissues/cells and G1 bladder tumor tissues. However, HYAL1 wild type is expressed in G2/G3 tumors and in invasive tumor cells. Stable transfection and HYAL1v1-specific antibody confirmed that the HYAL1 sequence from aa 301 to 330 is critical for hyaluronidase activity. All tumor cells and tissues mainly express HYAL3 variants. HYAL3v1 lacks a 30-aa sequence (299-328) present in HYAL3 protein, that is homologous to the 30-aa HYAL1 sequence. HYAL3v1, HYAL3v2 (aa 251-417 present in HYAL3 wild type), and HYAL3v3 (aa 251-417, but lacking aa 299-328), are enzymatically inactive. Although splicing of a single independent exon generates HYAL1v1 and HYAL3v1, internal exon splicing generates the other HYAL1/HYAL3 variants. These results demonstrate that alternative mRNA splicing controls cellular expression of enzymatically active hyaluronidase and may explain the elevated hyaluronidase levels in bladder/prostate cancer.
...
PMID:Regulation of hyaluronidase activity by alternative mRNA splicing. 1208 18


1 2 3 4 Next >>

---